| scholarly article | Q13442814 |
| P50 | author | Ronald P. Stolk | Q42384905 |
| Monique Breteler | Q19609784 | ||
| Albert Hofman | Q30121906 | ||
| P2093 | author name string | Grobbee DE | |
| Ott A | |||
| van Harskamp F | |||
| P433 | issue | 11 | |
| P921 | main subject | dementia | Q83030 |
| P304 | page(s) | 1392-1397 | |
| P577 | publication date | 1996-11-01 | |
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | Association of diabetes mellitus and dementia: the Rotterdam Study. | |
| P478 | volume | 39 |
| Q91817197 | A neural signature of metabolic syndrome |
| Q50422191 | A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease. |
| Q51453604 | Abeta40 is associated with cognitive function, body fat and physical fitness in healthy older adults. |
| Q36686081 | Adiponectin, leptin and IL-1 β in elderly diabetic patients with mild cognitive impairment. |
| Q45112544 | Aging and cognition |
| Q24300365 | Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria |
| Q51760876 | Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies. |
| Q26996487 | Alzheimer's disease and insulin resistance: translating basic science into clinical applications |
| Q33922757 | Alzheimer's disease and vascular dementia. Some points of confluence |
| Q47669564 | Alzheimer's disease: epidemiology |
| Q96686037 | Amylin and beta amyloid proteins interact to form amorphous heterocomplexes with enhanced toxicity in neuronal cells |
| Q27003342 | Amylin at the interface between metabolic and neurodegenerative disorders |
| Q38830948 | An Update on Type 2 Diabetes Mellitus as a Risk Factor for Dementia |
| Q48529784 | Angiotensin II, hypertension and angiotensin II receptor antagonism: Roles in the behavioural and brain pathology of a mouse model of Alzheimer's disease |
| Q44346607 | Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats |
| Q37688031 | Antidiabetic oral treatment in older people: does frailty matter? |
| Q90679431 | Antidiabetic therapies and Alzheimer disease |
| Q37676723 | Apolipoprotein E pathology in vascular dementia |
| Q36512147 | Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. |
| Q38183274 | Atypical antipsychotic-induced metabolic disturbances in the elderly |
| Q34609941 | Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. |
| Q34884241 | Bidirectional metabolic regulation of neurocognitive function |
| Q47168123 | Blood-brain barrier breakdown promotes macrophage infiltration and cognitive impairment in leptin receptor-deficient mice |
| Q26739671 | Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans |
| Q37025645 | Brain Insulin Signaling Is Increased in Insulin-Resistant States and Decreases in FOXOs and PGC-1α and Increases in Aβ1-40/42 and Phospho-Tau May Abet Alzheimer Development |
| Q38515312 | Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer's disease |
| Q38920531 | Breakdown of the Cerebrovasculature and Blood-Brain Barrier: A Mechanistic Link Between Diabetes Mellitus and Alzheimer's Disease. |
| Q36582769 | Cardiac risk factors and potential treatments in Alzheimer's disease |
| Q22242643 | Cardiovascular Risk Factors for Alzheimer's Disease |
| Q35688036 | Caspase-Cleaved Tau Co-Localizes with Early Tangle Markers in the Human Vascular Dementia Brain |
| Q38807699 | Celecoxib Alleviates Memory Deficits by Downregulation of COX-2 Expression and Upregulation of the BDNF-TrkB Signaling Pathway in a Diabetic Rat Model |
| Q36776088 | Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators |
| Q36659481 | Central nervous system involvement in diabetes mellitus |
| Q35106896 | Central proliferation and neurogenesis is impaired in type 2 diabetes and prediabetes animal models |
| Q37211768 | Cerebral arachidonate cascade in dementia: Alzheimer's disease and vascular dementia |
| Q52009127 | Cerebrospinal fluid levels of insulin in patients with Alzheimer's disease. |
| Q99207518 | Cerebrovascular risk factors impact frontoparietal network integrity and executive function in healthy ageing |
| Q50199042 | Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects |
| Q33720302 | Circulating Cellular Adhesion Molecules and Cognitive Function: The Coronary Artery Risk Development in Young Adults Study |
| Q36311526 | Cognitive decline and dementia in diabetes--systematic overview of prospective observational studies |
| Q30489305 | Cognitive dysfunction and diabetes mellitus |
| Q51971585 | Cognitive dysfunction in older subjects with diabetes mellitus: impact on diabetes self-management and use of care services. All Wales Research into Elderly (AWARE) Study. |
| Q43778438 | Cognitive function and information processing in type 2 diabetes |
| Q47955367 | Cognitive function in Japanese elderly with type 2 diabetes mellitus |
| Q26766681 | Common mechanisms involved in Alzheimer's disease and type 2 diabetes: a key role of chronic bacterial infection and inflammation |
| Q40506191 | Comorbid Depression and Diabetes as a Risk for Mild Cognitive Impairment and Alzheimer's Disease in Elderly Mexican Americans |
| Q42780146 | Complications of diabetes in elderly people |
| Q53346032 | Connecting type 2 diabetes to Alzheimer's disease. |
| Q35687048 | Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimer's Disease |
| Q28255422 | Coupling of mammalian target of rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2A- and glycogen synthase kinase-3 -dependent phosphorylation of Tau |
| Q33950420 | Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis |
| Q37543915 | Current concepts in vascular cognitive impairment and pharmacotherapeutic implications |
| Q39387188 | Cytoprotective effects of hesperetin and hesperidin against amyloid β-induced impairment of glucose transport through downregulation of neuronal autophagy |
| Q48178356 | DPP4 Inhibitors Can Be a Drug of Choice for Type 3 Diabetes: A Mini Review |
| Q37845454 | Dairy constituents and neurocognitive health in ageing |
| Q41882101 | Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin |
| Q30655342 | Dementia due to subcortical ischemic vascular disease |
| Q49387210 | Diabetes Mellitus and Alzheimer's Disease: The Protection of Epigallocatechin-3-gallate in Streptozotocin Injection-Induced Models |
| Q64917935 | Diabetes Mellitus as a Risk Factor for Parkinson's Disease: a Molecular Point of View |
| Q64095876 | Diabetes Mellitus-Related Fractional Glucose Uptake in Men and Women Imaged With F-FDG PET-CT |
| Q34141194 | Diabetes and dementia |
| Q53227860 | Diabetes and dementia in long-term care. |
| Q33398039 | Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis |
| Q99240071 | Diabetes as a Risk Factor for Abnormal Cognition Development |
| Q35633136 | Diabetes mellitus and cognitive performance in older women |
| Q36655872 | Diabetes mellitus and dementia. |
| Q37765503 | Diabetes type II: a risk factor for depression-Parkinson-Alzheimer? |
| Q30715447 | Diabetes, dysglycemia and cognitive dysfunction |
| Q64118633 | Diet-Derived Fatty Acids, Brain Inflammation, and Mental Health |
| Q53247397 | Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study. |
| Q26783276 | Does Intensive Glucose Control Prevent Cognitive Decline in Diabetes? A Meta-Analysis |
| Q35618911 | Does diabetes protect or provoke Alzheimer's disease? Insights into the pathobiology and future treatment of Alzheimer's disease |
| Q50716216 | Earlier age of dementia onset and shorter survival times in dementia patients with diabetes. |
| Q44555824 | Effect of age and glucoregulation on cognitive performance |
| Q24250162 | Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia |
| Q36964574 | Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function -- role of glucose metabolism and insulin signalling |
| Q41865888 | Effects of Astragalus polysaccharides on memory impairment in a diabetic rat model |
| Q35613905 | Effects of exercise on brain functions in diabetic animal models |
| Q34489699 | Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease |
| Q27003253 | Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain |
| Q37935917 | Emerging roles of pathogens in Alzheimer disease |
| Q36870079 | Environmental and dietary risk factors in Alzheimer's disease |
| Q37285389 | Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder? |
| Q51981750 | Factors associated with vascular dementia in an elderly community population. |
| Q35594774 | Flos Puerariae Extract Ameliorates Cognitive Impairment in Streptozotocin-Induced Diabetic Mice |
| Q27009988 | Food for thought: the role of appetitive peptides in age-related cognitive decline |
| Q57337684 | Genetic, physiological, and lifestyle predictors of mortality in the general population |
| Q35070673 | Glucagon-like peptide-1, diabetes, and cognitive decline: possible pathophysiological links and therapeutic opportunities. |
| Q50435098 | Glucocorticoid-mediated activation of GSK3β promotes tau phosphorylation and impairs memory in type 2 diabetes |
| Q36605311 | Glycogen synthase kinase-3 inhibition prevents learning deficits in diabetic mice |
| Q28195662 | Guidelines for Improving the Care of the Older Person with Diabetes Mellitus |
| Q91540525 | Higher GABA concentration in the medial prefrontal cortex of Type 2 diabetes patients is associated with episodic memory dysfunction |
| Q35149197 | Hypertension and diabetes as risk factors for dementia: A secondary post-hoc analysis from north-west India |
| Q33588229 | Hypertension, cerebrovascular impairment, and cognitive decline in aged AβPP/PS1 mice |
| Q47551833 | Impact of diabetes on caregiver stress in patients with Alzheimer's disease: data from the ICTUS study |
| Q30978064 | Impact of diabetes on cognitive function and brain structure. |
| Q59327762 | Impact of pharmacological treatment of diabetes mellitus on dementia risk: systematic review and meta-analysis |
| Q94382124 | Impaired Cerebral Autoregulation-A Common Neurovascular Pathway in Diabetes may Play a Critical Role in Diabetes-Related Alzheimer's Disease |
| Q48370238 | Improved cerebral energetics and ketone body metabolism in db/db mice |
| Q33927061 | Increased Alzheimer's disease neuropathology is associated with type 2 diabetes and ApoE ε.4 carrier status |
| Q36772914 | Increased Spontaneous Central Bleeding and Cognition Impairment in APP/PS1 Mice with Poorly Controlled Diabetes Mellitus |
| Q34461012 | Increased mRNA Levels of TCF7L2 and MYC of the Wnt Pathway in Tg-ArcSwe Mice and Alzheimer's Disease Brain |
| Q47556291 | Insulin Resistance is Associated with Cognitive Decline Among Older Koreans with Normal Baseline Cognitive Function: A Prospective Community-Based Cohort Study. |
| Q35674377 | Insulin and neurodegenerative disease: shared and specific mechanisms |
| Q44482048 | Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype |
| Q48228017 | Insulin induces tyrosine phosphorylation of the insulin receptor and SHC, and SHC/GRB2 association in cerebellum but not in forebrain cortex of rats |
| Q36528274 | Insulin receptor signaling mediates APP processing and β-amyloid accumulation without altering survival in a transgenic mouse model of Alzheimer's disease |
| Q37942690 | Insulin resistance and pathological brain ageing |
| Q33604874 | Insulin, cognition, and dementia |
| Q43477250 | Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. |
| Q92688640 | Interferon-γ as a Potential Link between Diabetes Mellitus and Dementia |
| Q36582781 | Interventions for heart disease and their effects on Alzheimer's disease |
| Q34028845 | Is apolipoprotein E4 an important risk factor for vascular dementia? |
| Q34588663 | Is pharmacological prevention of Alzheimer's a realistic goal? |
| Q35236550 | Is the distinction between Alzheimer's disease and vascular dementia possible and relevant? |
| Q41767433 | L-arginine and Alzheimer's disease. |
| Q51566639 | Lack of associations between serum leptin, a polymorphism in the gene for the beta 3-adrenergic receptor and glucose tolerance in the Dutch population. |
| Q39478082 | Mango leaf extract improves central pathology and cognitive impairment in a type 2 diabetes mouse model. |
| Q42959238 | Measurement of cerebral oxidative glucose consumption in patients with type 1 diabetes mellitus and hypoglycemia unawareness using (13)C nuclear magnetic resonance spectroscopy |
| Q35678012 | Measures of adiposity and dementia risk in elderly persons |
| Q37214556 | Metabolic syndrome and Alzheimer's disease: a link to a vascular hypothesis? |
| Q36880464 | Metabolic syndrome and cognitive decline in early Alzheimer's disease and healthy older adults |
| Q38416332 | Metformin Facilitates Amyloid-β Generation by β- and γ-Secretases via Autophagy Activation |
| Q47703267 | Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline. |
| Q33956934 | Midlife predictors of Alzheimer's disease |
| Q47756026 | Mitogenic factors accelerate later-age diseases: insulin as a paradigm |
| Q36220289 | Models and mechanisms for hippocampal dysfunction in obesity and diabetes |
| Q48513312 | Modifications of tau protein after cerebral ischemia and reperfusion in rats are similar to those occurring in Alzheimer's disease - Hyperphosphorylation and cleavage of 4- and 3-repeat tau. |
| Q37856779 | Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function |
| Q53362576 | Neurodegeneration and energy metabolism: from chemistry to clinics. |
| Q49808096 | Neuroinflammation in Alzheimer's Disease: Pleiotropic Roles for Cytokines and Neuronal Pentraxins |
| Q33181556 | Neurotoxicity of advanced glycation end-products for cultured cortical neurons |
| Q37306767 | New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. |
| Q46287704 | Non-alcoholic fatty liver induces insulin resistance and metabolic disorders with development of brain damage and dysfunction. |
| Q37902373 | Non-psychiatric comorbidity associated with Alzheimer's disease. |
| Q48100959 | Novel calcium-related targets of insulin in hippocampal neurons |
| Q38921866 | Oral inflammation and infection, and chronic medical diseases: implications for the elderly. |
| Q34192388 | Overview and perspective on the therapy of Alzheimer's disease from a preclinical viewpoint |
| Q35149972 | Plasma Amylin and Cognition in Diabetes in the Absence and the Presence of Insulin Treatment |
| Q48231681 | Plasma protein glycation in Alzheimer's disease |
| Q48180991 | Potential hippocampal region atrophy in diabetes mellitus type 2: a voxel-based morphometry VSRAD study |
| Q92556485 | Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease |
| Q37854474 | Prevention of dementia: Role of vascular risk factors and cerebral emboli |
| Q57271511 | Prospect-EPIC Utrecht: study design and characteristics of the cohort population. European Prospective Investigation into Cancer and Nutrition |
| Q24635626 | Protective and damaging effects of stress mediators: central role of the brain |
| Q37614594 | Protein Tyrosine Phosphatase 1B (PTP1B): A Potential Target for Alzheimer's Therapy? |
| Q28076517 | Psychopathology and psychotherapeutic intervention in diabetes: particularities, challenges, and limits |
| Q47615971 | Redefining neuroendocrinology: Epigenetics of brain-body communication over the life course |
| Q49687656 | Reduction of Cognitive Decline in Patients with or at High Risk for Diabetes |
| Q48193301 | Relationship Between the Induction of RAGE Cell-Surface Antigen and the Expression of Amyloid Binding Sites |
| Q88654489 | Retromer Dysfunction and Neurodegenerative Disease |
| Q34149357 | Review of cerebral microangiopathy and Alzheimer's disease: relation between white matter hyperintensities and microbleeds. |
| Q51026220 | Risk factors for cognitive dysfunction in CKD and hypertensive subjects. |
| Q37889475 | Risk profiles of Alzheimer disease |
| Q40297061 | Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study |
| Q33677202 | Role of insulin signaling impairment, adiponectin and dyslipidemia in peripheral and central neuropathy in mice |
| Q33690300 | Short-term longitudinal trends in cognitive performance in older adults with type 2 diabetes |
| Q47784347 | Sildenafil Improves Vascular and Metabolic Function in Patients with Alzheimer's Disease |
| Q40746525 | Similar pattern of peripheral neuropathy in mouse models of type 1 diabetes and Alzheimer's disease |
| Q51890277 | Social network, cognitive function, and dementia incidence among elderly women. |
| Q47333026 | Statin Use is Associated with Better Cognitive Function in Elderly with Type 2 Diabetes |
| Q33942765 | Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. |
| Q38621253 | Strategies for dementia prevention: latest evidence and implications |
| Q30844186 | Structural imaging measures of brain aging |
| Q55306046 | Sweet Mitochondria: A Shortcut to Alzheimer's Disease. |
| Q35738734 | Synergistic exacerbation of mitochondrial and synaptic dysfunction and resultant learning and memory deficit in a mouse model of diabetic Alzheimer's disease |
| Q36710935 | The As and Ds of stress: metabolic, morphological and behavioral consequences |
| Q42282735 | The Effect of Green Tea Extract on Oxidative Stress and Spatial Learning in Streptozotocin-diabetic Rats |
| Q37334681 | The Effect of Undiagnosed Diabetes on the Association Between Self-Reported Diabetes and Cognitive Impairment Among Older Mexican Adults. |
| Q64104414 | The Role of Insulin-Like Growth Factors and Insulin-Like Growth Factor-Binding Proteins in the Nervous System |
| Q48790631 | The activation of the Akt/PKB signalling pathway in the brains of clozapine-exposed rats is linked to hyperinsulinemia and not a direct drug effect |
| Q50050282 | The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease. |
| Q89594509 | The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation |
| Q43515186 | The effect of gamma-linolenic acid-alpha-lipoic acid on functional deficits in the peripheral and central nervous system of streptozotocin-diabetic rats. |
| Q73437037 | The effect of insulin and glucose on the plasma concentration of Alzheimer's amyloid precursor protein |
| Q42947848 | The final frontier: how does diabetes affect the brain? |
| Q90973905 | The impact of comorbid depression-diabetes on proteomic outcomes among community-dwelling Mexican Americans with mild cognitive impairment |
| Q36255194 | The link between cholesterol and Alzheimer's disease |
| Q37765832 | The link between iron, metabolic syndrome, and Alzheimer's disease |
| Q35980002 | The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function |
| Q35841727 | The relationships between atherosclerosis, heart disease, type 2 diabetes and dementia |
| Q35618918 | The role of cardiovascular risk factors in Alzheimer's disease |
| Q35186622 | The role of the retromer complex in aging-related neurodegeneration: a molecular and genomic review |
| Q33828868 | Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice |
| Q88925402 | Type 2 Diabetes Mellitus Is Associated with Social Recognition Memory Deficit and Altered Dopaminergic Neurotransmission in the Amygdala |
| Q47408299 | Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. |
| Q36926037 | Type 2 diabetes and risk of cognitive impairment and dementia |
| Q35184690 | Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology |
| Q78944637 | Type 2 diabetes mellitus and cognition: an understudied issue in women's health |
| Q92995548 | Variation of HbA1c affects cognition and white matter microstructure in healthy, young adults |
| Q26820823 | Vascular aspects of cognitive impairment and dementia |
| Q34680483 | Vascular basis for brain degeneration: faltering controls and risk factors for dementia |
| Q37085101 | Vascular cognitive impairment: current concepts and clinical developments |
| Q53235144 | Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. |
| Q33808042 | Vascular risk factors and Alzheimer's disease |
| Q33950366 | Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. |
| Q33905844 | Vascular risk factors: imaging and neuropathologic correlates |
| Q36622813 | Vps10 family proteins and the retromer complex in aging-related neurodegeneration and diabetes |
| Q53427297 | [Diabetes mellitus and cognitive decline]. |
| Q55455350 | iPSC-derived familial Alzheimer's PSEN2 N141I cholinergic neurons exhibit mutation-dependent molecular pathology corrected by insulin signaling. |
Search more.